ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Medicare must recognize obesity as a chronic disease and provide coverage for the treatments that can help those who struggle ...
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list ...
The Food and Drug Administration allows this kind of compounding ... didn't have what's called a sterile compounding license. The obesity drugs made by compounding pharmacies are given by ...